“Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs”, JIMKI, p. 10, Dec. 2025, doi: 10.53366/jimki.vi.961.